ClinicalTrials.gg
RecruitingNCT07349173Updated Mar 16, 2026

Peripersonal Space Representation in Upper Limb Segmental Exclusion

An observational study in Segmental Exclusion Syndrome, Complex Regional Pain Syndrome (CRPS) and Upper Limb Neglect (Peripheral), sponsored by Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Complex Regional Pain Syndromes with a site in France — 6 open to participants now, 6 under way, none of them phase 3. Complex Regional Pain Syndromes · France.

Started
2025
the only one that year
Observational
4 of 17
2 open now
Registered
15th of 17
by date

Among the 17 studies in Complex Regional Pain Syndromes with a site in France, this one is the only one that started in 2025, is one of 4 observational ones, and was the 15th registered.

Complex Regional Pain Syndromes

206 studies on the registry are indexed under Complex Regional Pain Syndromes; 54 are open to participants now.

Browse Complex Regional Pain Syndromes studies →

Open to participants now

6 of the 17 studies in Complex Regional Pain Syndromes with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 41 Complex Regional Pain Syndromes studies recruiting now, 19 (46%) set no upper age limit and 16 (39%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Complex Regional Pain Syndromes with a site in France, or all of them as a file.
02

Study summary

This study aims to evaluate the representation of action peripersonal space (PPS) in subjects suffering from unilateral segmental exclusion syndrome of the upper limb compared to healthy control subjects. Segmental exclusion is defined by non-use or under-use of a limb segment without central nervous system damage. The study hypothesizes that this syndrome leads to a modification (shrinkage) of the PPS representation. Participants will perform reachability judgments in a Virtual Reality (VR) environment.

Read the detailed description

Segmental exclusion syndrome often occurs after limb trauma and manifests as a neglect-like behavior of peripheral origin, sometimes associated with Complex Regional Pain Syndrome (CRPS). The study explores whether the lack of limb use affects the representation of peripersonal space (PPS)-the space immediately surrounding the body where interactions with objects occur.

The study is monocentric, observational, with a matched control group. Participants will undergo:

Clinical assessment (questionnaires on pain, anxiety, body perception, and kinesiophobia).

A Virtual Reality (VR) test (approx. 40 minutes). In VR, participants will judge whether a cylinder presented at different distances and angles is reachable without moving (Perceived Reachable Distance - DMA-p). This will be compared to their Real Reachable Distance (DMA-r).

The goal is to measure the error of judgment to assess PPS representation and check for correlations with body schema disturbances or functional impairment

03

Conditions studied

  • Segmental Exclusion Syndrome
  • Complex Regional Pain Syndrome (CRPS)
  • Upper Limb Neglect (Peripheral)

Keywords

  • Peripersonal Space
  • Virtual Reality
  • Body Schema
  • Reachability Judgment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

he study population consists of two groups recruited at the Institut Régional de Réadaptation (Centre Louis Pierquin, UGECAM Nord-Est) in Nancy, France.

Patients with Exclusion: Participants are selected from patients receiving routine care (full hospitalization or day hospital) at the center. They are identified based on a functional assessment ("Bilan 400 points") showing specific impairments related to unilateral upper limb exclusion evolving for more than 3 months.

Healthy Controls: Asymptomatic volunteers are recruited through the social or family network of the investigators and current participants, as well as via posters displayed in the UGECAM centers.

Eligibility criteria

Inclusion Criteria (patients):

  • Age ≥ 18 years.
  • Presenting unilateral exclusion symptom of the upper limb or part of the hand evolving for > 3 months.
  • No to force work in daily activities.
  • For patients with finger exclusion: at least 2 perturbed items related to exclusion on tests 3 and 4 of the "Bilan 400 points".
  • Affiliated to a social security scheme.
  • Able to understand simple orders.

Inclusion Criteria (Controls):

  • Age ≥ 18 years.
  • No history of upper limb impairment with sequelae.

Exclusion Criteria (All):

  • Visual impairments.
  • Central neurological pathology.
  • Unstabilized psychiatric pathology.
  • Communication or comprehension difficulties.
  • Under legal protection or unable to consent.
  • Pregnant or breastfeeding women.
  • Cervical pathology contraindicating VR headset use.
  • Epilepsy.
  • Upper limb pathology unrelated to exclusion.
  • Inability to stand for 40 minutes.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with Exclusion

    Patients presenting with unilateral segmental exclusion of the upper limb or part of the hand evolving for more than 3 months.

    Behavioral: Reachability Judgment Task in VR.

  • Healthy Controls

    symptomatic volunteers with no history of upper limb impairment with sequelae.

    Behavioral: Reachability Judgment Task in VR.

Interventions

  • BehavioralReachability Judgment Task in VR.

    Participants wear an Oculus Quest 2 VR headset. They first perform a motor task to measure Real Reachable Distance (DMA-r). Then, they perform a perceptual task where they must judge, without moving, if a virtual object is reachable (DMA-p). The test evaluates different spatial planes (front, 45° right, 45° left) and heights (shoulder, navel).

06

What researchers measure

Primary outcomes

  1. Judgment Error of Reachability

    The Judgment Error of Reachability is a single composite metric calculated as: ((DMA-p - DMA-r) / DMA-r) × 100, expressed as a percentage (%). Both DMA-p (Perceived Maximum Reachable Distance) and DMA-r (Real Maximum Reachable Distance) are measured in centimeters, and their ratio yields a single dimensionless percentage score.

    Time frame: Day 1 (During the 40-minute VR assessment)

Secondary outcomes

  1. Body Perception Disturbance Score

    Assessed using the Bath CRPS Body Perception Disturbance Scale (French version). Scores range from 0 to 57, with higher scores indicating greater disturbance.

    Time frame: Day 1 (Before VR task)

  2. Functional Impairment Score (400-Point Hand Assessment)

    Evaluated using the 400-Point Hand Assessment, which measures functional hand use. The score ranges from 0 to 400, where higher scores indicate better functional performance (better outcome).

    Time frame: Day 1

  3. Anxiety and Depression Score (HAD)

    Hospital Anxiety and Depression Scale. Scores range from 0 to 21 for each dimension (Anxiety and Depression).

    Time frame: Day 1

  4. Kinesiophobia Score (Tampa Scale)

    Tampa Scale for Kinesiophobia (TSK). Assesses fear of movement. Scores range to 68; \>40 indicates significant kinesiophobia.

    Time frame: Day 1

  5. Pain Catastrophizing Score (PCS)

    Pain Catastrophizing Scale. Scores range from 0 to 52.

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
  • Institut Régional de Médecine Physique et de Réadaptation (IRR), Centre Louis Pierquin.
    Nancy, 54000, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Jul 2027, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2026
First posted
Jan 16, 2026
StartActual
Dec 4, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Jan 2028
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07349173
Lead sponsor
Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Dec 4, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Mar 16, 2026

Study contacts

Amélie Touillet, MD
Contact
amelie.touillet@ugecam.assurance-maladie.fr
+33 3 83 52 98 80
Jonahtan Pierret, PhD
Contact
jonathan.pierret@ugecam.assurance-maladie.fr
+33 3 83 52 67 61

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion